Journal Article
Validation Studies
Add like
Add dislike
Add to saved papers

The average predictive validity of intimate partner violence risk assessment instruments.

The field of intimate partner violence (IPV) risk assessment (predicting recidivism, lethality) is fast growing, and the majority of research examining the predictive validity of IPV risk assessment instruments has been conducted in the past decade. This study examines the average predictive validity weighted by sample size of five stand alone IPV risk assessment instruments that have been validated in multiple research studies using the Receiver Operating Characteristic Area Under the Curve (AUC). The Ontario Domestic Assault Risk Assessment (ODARA) has the highest average weighted AUC (=.666, k=5) followed, in order of most to least predictive, by the Spousal Assault Risk Assessment (SARA; AUC=.628, k=6), the Danger Assessment (DA; AUC=.618, k=4), the Domestic Violence Screening Inventory (DVSI; AUC=.582, k=3), and the Kingston Screening Instrument for Domestic Violence (K-SID; AUC=.537, k=2). The effect size for the average AUCs for IPV risk assessment instruments is small, with the exception of a medium effect size for the ODARA. Of the 20 measures of predictive validity included in this analysis, the risk assessment was administered correctly in nine (45%). IPV risk assessment is relatively new, and the use of proxy instruments and utilization of risk assessment instruments in settings for which they were not created is widespread. While waiting for a more rigorous body of research, factors in addition to predictive validity must be taken into consideration (e.g., setting, outcome, skills of the assessor, access to information) when choosing which risk assessment instrument is appropriate for use in a particular practice setting.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app